BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) saw a 17.71% surge in stock price on Friday, reaching $61.15 per share. The company acquired Amicus Therapeutics for nearly $5 billion, with shares priced at $14.50 each, a 33% premium. The acquisition will be funded through cash on hand and non-convertible debt financing. This move is expected to increase BioMarin’s revenue growth and strengthen its financial outlook. The company anticipates a rise in CAGR through 2030, with combined net product revenues of $599 million from the acquired treatments. CEO Alexander Hardy is optimistic about the transaction’s value for patients, employees, and shareholders.

Read more at Yahoo Finance: BioMarin (BMRN) Jumps 17.7% on $5-Billion Merger with Amicus